Immunotherapy with the anti-GD<sub>2</sub> antibody (Ab) ch14.18/CHO in combination with interleukin 2 (IL-2) has improved survival of high-risk neuroblastoma (NB) patients.
Fifty-three high-risk NB patients received up to 6 cycles of 100 mg/m<sup>2</sup> ch14.18/CHO (d8-17) as LTI combined with 6 × 10<sup>6</sup> IU/m<sup>2</sup> s.c. IL-2 (d1-5; 8-12) and 160 mg/m<sup>2</sup> oral RA (d19-32).
Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial.
<b>Purpose:</b> In 2010, a Children's Oncology Group (COG) phase III randomized trial for patients with high-risk neuroblastoma (ANBL0032) demonstrated improved event-free survival (EFS) and overall survival (OS) following treatment with an immunotherapy regimen of dinutuximab, GM-CSF, IL2, and isotretinoin compared with treatment with isotretinoin alone.
Dinutuximab (Unituxin, United Therapeutics) is a novel monoclonal antibody recently approved for use in combination with granulocyte- macrophage colony-stimulating factor, interleukin-2, and isotretinoin for the treatment of pediatric patients with high-risk neuroblastoma.